Amir M. Emtiazjoo, MD, MSc
Medical Director, Lung Transplant Program
Associate Professor of Medicine
Email: Amir.Emtiazjoo@medicine.ufl.edu
TEL: 352.273.8737
Degree/Program |
Institution |
Field/Specialty |
MD | Tehran University of Medical Sciences | Medicine |
Residency | University of California at San Francisco (UCSF)-Fresno | Internal Medicine |
Fellowship | Indiana University School of Medicine | Pulmonary and Critical Care Medicine |
Fellowship | Stanford University | Lung and Heart-Lung Transplant |
MSc | McGill University | Molecular Biology |
Clinical Interests:
- Lung & Heart-lung transplantation
- Advanced Lung Disease
- Antibody mediated lung allograft rejection
- Management of highly sensitized Lung transplant candidates
Research Interests:
- Dr. Emtiazjoo’s research focuses on lung transplant immunology. He has studied the role of humoral immunity (alloimmunity & atuoimmunity) in development of Primary Graft Dysfunction (PGD) and allograft dysfunction post lung transplantation.
Honors and Awards:
- The American College of Chest Physicians (ACCP), Best case presentation. CHEST 2011, Honolulu, HI (10/2011)
- Montreal Centre for Experimental Therapeutics in Cancer (MCETC). Young Investigator Research Grant, McGill University, Montreal, Quebec, Canada (06/2002-06/2044)
Publications:
Peer Reviewed Original Publications
- Shah RJ, K Rothaar, Emtiazjoo AM, S Frye, JM Diamond, E Cantu III , DJ Lederer, VN Lama, J Orens, P Shah, A Weinacker, G Dhillon , S Bhorade , KM Wille, LB Ware, SM Palmer, L Snyder, M Hartwig , M Crespo, J McDyer, DS Wilkes, JD Christie. The role of antibodies to collagen V in the development of Primary Graft Dysfunction. JHLT (submitted)
- Biswas A, Ataya A, Chandrashekaran S, Salgado JC, Machuca T, Emtiazjoo AM. A 42-year-old woman with Anemia, Shock and Ischemic Stroke After Lung Transplantation. CHEST (accepted-in press).
- Ataya A, Biswas A, Chandrashekaran S, Salgado JC, Goldstein SS, Emtiazjoo AM. A 48-Year-Old Man with Leukopenia, Jaundice, and Skin Rash After Lung Transplantation. CHEST 2016 Dec;150(6):e167-e170
- Shah RJ, K Rothaar, Emtiazjoo AM, S Frye, JM Diamond, E Cantu III , DJ Lederer, VN Lama, J Orens, P Shah, A Weinacker, G Dhillon , S Bhorade , KM Wille, LB Ware, SM Palmer, L Snyder, M Hartwig , M Crespo, J McDyer, DS Wilkes, JD Christie. The role of antibodies to collagen V in the development of Primary Graft Dysfunction. JHLT (submitted)
- Emtiazjoo AM, Shah RJ, S Frye, JM Diamond, E Cantu III , DJ Lederer, VN Lama, J Orens, P Shah, A Weinacker, S Bhorade , KM Wille, LB Ware, SM Palmer, L Snyder, M Hartwig , M Crespo, J McDyer, DS Wilkes, JD Christie. Plasma Complement C5a is Associated with Risk of Primary Graft and Mortality after Lung Transplantation Dysfunction. Am J Respir Crit Care Med. 2014 Jun 15;189(12):1564-7
- Vittal R, Fisher A, Brown K, Mickller E, Gu H, Emtiazjoo AM, Cummings O,Wilkes DS. Type V Collagen Induced Tolerance Suppresses Collagen Deposition TGF-beta and Associated Transcripts in Pulmonary Fibrosis. PLoS One 2013 Oct 21;8(10):e76451
- Emtiazjoo AM, Wilkes DS. Humoral Immunity and Development of Obliterative Bronchiolitis Post Lung Transplantation – is there a Link? Am J Respir Cell Mol Biol; 2013 Feb;48(2):145-9
- Van Der Veer J, Lewis R, Emtiazjoo AM, Wheat LJ, Allen S, Hage C. Cross-reactivity in the Platelia™ Aspergillus enzyme immunoassay caused by blastomycosis. Med Mycol. 2012 May;50(4):396-8)
- Emtiazjoo AM. Negatively charged amino acids flanking the LXXLL motifs decrease the interaction between co-activators and estrogen receptor alpha, but not beta, using Bioluminescence Resonance Energy Transfer (BRET). Master’s thesis, McGill University, Montreal, Canada.
Editorial
- Emtiazjoo AM, Shillings RA. Preventing the NET Negative in Primary Graft Dysfunction. Am J Respire Crit Care Med. 2015 Feb 15;191(4):368-9
Book Chapter
- Salgado JC, Chandrachekaran S, Emtiazjoo AM. Intensive Care Unit Management of Lung Transplant patients. Textbook of Critical Care, Vincent JL 7th edition, Elsevier2017 Jan; 158:1099-1105.